Raising capital through an IPO is the most expensive way to do it. That’s why there’s every chance they will use BIOAQ to go public at the same time to fund their huge expansion plans
Visolis IS an emerging startup with virtually NO assets. LCY is fronting the cash.
Several posters have already made the argument that BIOA is the perfect shell for a reverse merger to preserve $237M NOL's for the new owners. It could be done and could provide liquidity back to LCY (KKR) in a relatively short period of time. I would not be surprised to see NewCo reversed into BIOA with a very quick name and ticker change.
I would assume all that to happen with uplisting back to NYSE after getting the PPS where it needs to be.
News 
Market Data 
Discover 
